市場調査レポート

商品コード

1533606

がん診断の市場規模、シェア、成長分析：製品別、技術別、用途別、エンドユーザー別、地域別 - 産業予測、2024年～2031年

Cancer Diagnostics Market Size, Share, Growth Analysis, By Product, By Technology, By Application, By End User, By Region - Industry Forecast 2024-2031

出版日: 2024年08月06日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

がん診断市場は、2022年に1,123億米ドルとなり、2023年の1,200億4,000万米ドルから上昇し、予測期間（2024年～2031年）のCAGRは6.89%で、2031年までには2,045億5,000万米ドルに達すると予測されています。

がん診断では、さまざまな細胞タイプ、タンパク質、がん腫瘍の存在を示す指標を特定します。この分野の成長は、世界のがん罹患率の増加、早期発見に対する意識の高まり、がん研究開発への資金提供の増加、診断検査の技術進歩、民間診断センターの増加などが主要な要因です。SkyQuestの詳細分析によると、2024年には約200万1,140人の新規がん患者が発生すると予想されており、これはがん診断市場に直接的な影響を与えると思われます。さらに、ヘルスケア支出の増加や政府の支援策が市場成長に寄与しています。にもかかわらず、多額の資本コスト、高い放射線被曝の可能性、熟練した専門家の不足といった課題も市場に影響を与えています。アジア太平洋のような新興地域は、ヘルスケアインフラの改善やがん検診を推進する政府の取り組みにより、急速な成長を遂げています。さらに、遠隔医療やモバイルヘルスアプリなどのデジタルヘルス技術の採用により、遠隔モニタリングや個別化ケアが強化されています。しかし、高いコスト、規制上の課題、データプライバシーに関する懸念は、市場の潜在力を十分に活用するために対処すべき大きな課題として残っています。

市場概要
消耗品
- 抗体
- キット・試薬
- プローブ
- その他の消耗品
機器
- 病理学に基づく機器
スライド染色システム
組織処理システム
Cellプロセッサ
PCR機器
NGS機器
マイクロアレイ
その他の病理学に基づく機器
- 画像機器
CTシステム
超音波システム
MRIシステム
マンモグラフィーシステム
核イメージングシステム
- 生検器具

世界のがん診断市場：技術別

市場概要
IVD検査
- ポリメラーゼ連鎖反応
- In Situハイブリダイゼーション
- 免疫組織化学
- 次世代シーケンシング
- 免疫測定
- マイクロアレイ
- フローサイトメトリー
- その他のIVD技術
イメージング技術
- 磁気共鳴画像
- コンピュータ断層撮影
- 核イメージング
- マンモグラフィー
- 超音波
生検

世界のがん診断市場：用途別

市場概要
乳がん
肺がん
大腸がん
悪性黒色腫
その他のがん

世界のがん診断市場：エンドユーザー別

市場概要
病院
診断検査室
その他

世界のがん診断市場規模：地域別

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主要な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Abbott Laboratories（US）
Agilent Technologies（US）
Becton, Dickinson and Company（BD）（US）
bioMerieux SA（France）
Danaher Corporation（US）
F. Hoffmann-La Roche Ltd.（Switzerland）
GE Healthcare（US）
Hologic, Inc.（US）
Illumina, Inc.（US）
Koninklijke Philips N.V.（Netherlands）
Merck KGaA（Germany）
Myriad Genetics, Inc.（US）
QIAGEN N.V.（Netherlands）
Siemens Healthineers AG（Germany）
Sysmex Corporation（Japan）
Thermo Fisher Scientific Inc.（US）
Exact Sciences Corporation（US）
Guardant Health, Inc.（US）
Caris Life Sciences（US）
Foundation Medicine, Inc.（US）

Product Code: SQMIG35J2078

Cancer Diagnostics Market was valued at USD 112.3 Billion in 2022 and is expected to rise from USD 120.04 Billion in 2023 to reach a value of USD 204.55 Billion by 2031, at a CAGR of 6.89% during the forecast period (2024-2031).

Cancer diagnostics involves identifying various cell types, proteins, and indicators that signal the presence of cancerous tumors. The growth in this field is largely driven by the increasing global incidence of cancer, heightened awareness of early detection, increased funding for cancer research and development, technological advancements in diagnostic testing, and a rise in private diagnostic centers. According to SkyQuest's detailed analysis, around 2,001,140 new cancer cases are expected in 2024, which will have a direct impact on the cancer diagnostics market. Furthermore, rising healthcare expenditure and supportive government initiatives are contributing to market growth. Despite this, challenges such as significant capital costs, potential high radiation exposure, and a shortage of skilled professionals also affect the market. Emerging regions like Asia-Pacific are experiencing rapid growth due to improvements in healthcare infrastructure and government initiatives promoting cancer screening. Additionally, the adoption of digital health technologies, including telemedicine and mobile health apps, is enhancing remote monitoring and personalized care. However, high costs, regulatory challenges, and data privacy concerns remain major issues to address in order to fully leverage the market potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Diagnostics Market Segmental Analysis

The cancer diagnostics market is segmented based on the Product, Technology, Application, End User and region. Based on the Product, the cancer diagnostics market is segmented into Consumables (Antibodies, Kits & Reagents, Probes, Others) and Instruments (Pathology-Based Instruments [Slide Staining Systems, Tissue Processing Systems, Cell Processors, PCR Instruments, NGS Instruments, Microarrays, Others], Imaging Instruments [CT Systems, Ultrasound Systems, MRI Systems, Mammography Systems, Nuclear Imaging Systems], Biopsy Instruments). Based on the Application, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, and Others. Based on the Technology, the market is segmented into IVD Testing (Polymerase Chain Reaction, In Situ Hybridization, Immunohistochemistry, Next-Generation Sequencing, Immunoassay, Microarray, Flow Cytometry, Others), Imaging Technologies (Magnetic Resonance Imaging, Computed Tomography, Nuclear Imaging, Mammography, Ultrasound), and Biopsies. Based on the End User, the market is segmented into Hospitals, Diagnostic Laboratories, Others. Based on Region it is categorized into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa.

Drivers of the Global Cancer Diagnostics Market

Growing government initiatives to promote the benefits of early diagnosis are expected to drive significant growth in the cancer diagnostics market in the near future. In developing and underdeveloped regions, awareness and availability of cancer diagnostic products are relatively low. To address this issue, both private and government organizations are launching awareness campaigns to educate the public about the importance of early diagnosis.

Restraints in the Global Cancer Diagnostics Market

Exposure to radiation from CT scans and X-rays poses health risks, including an increased likelihood of developing serious conditions such as cancer. These potential side effects can lead to decreased patient compliance and acceptance of radiation therapy, which may, in turn, impact the overall use of radiation in cancer diagnosis and treatment.

Market Trends of the Global Cancer Diagnostics Market

The interest in early cancer detection through simple blood tests, known as liquid biopsies, is rapidly growing. These tests offer a less invasive alternative to traditional diagnostic methods and have been gaining traction for their potential to identify cancer at an early stage. Recent research indicates that blood tests, which analyze various markers including genes and proteins, could be sensitive enough to diagnose cancer. This emerging diagnostic approach holds promise for improving early detection and potentially enhancing treatment outcomes.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Supply Chain Analysis
Patent Analysis
Trade Analysis
Ecosystem of the Market
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Global Cancer Diagnostic Market by Product

Market Overview
Consumables
- Antibodies
- Kits & Reagents
- Probes
- Other Consumables
Instruments
- Pathology-Based Instruments
Slide Staining Systems
Tissue Processing Systems
Cell Processors
PCR Instruments
NGS Instruments
Microarrays
Other Pathology-Based Instruments
- Imaging Instruments
CT Systems
Ultrasound Systems
MRI Systems
Mammography Systems
Nuclear Imaging Systems
- Biopsy Instruments

Global Cancer Diagnostic Market By Technology

Market Overview
IVD Testing
- Polymerase Chain Reaction
- In Situ Hybridization
- Immunohistochemistry
- Next-Generation Sequencing
- Immunoassay
- Microarray
- Flow Cytometry
- Other IVD Technologies
Imaging Technologies
- Magnetic Resonance Imaging
- Computed Tomography
- Nuclear Imaging
- Mammography
- Ultrasound
Biopsies

Global Cancer Diagnostic Market By Application

Market Overview
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Other Cancers

Global Cancer Diagnostic Market By End User

Market Overview
Hospitals
Diagnostic Laboratories
Others

Global Cancer Diagnostic Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Abbott Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (BD) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bioMerieux SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Koninklijke Philips N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Caris Life Sciences (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Foundation Medicine, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments